Literature DB >> 21234554

Cooperation of phosphates and carboxylates controls calcium oxalate crystallization in ultrafiltered urine.

Bernd Grohe1, Brian P H Chan, Esben S Sørensen, Gilles Lajoie, Harvey A Goldberg, Graeme K Hunter.   

Abstract

Osteopontin (OPN) is one of a group of proteins found in urine that are believed to limit the formation of kidney stones. In the present study, we investigate the roles of phosphate and carboxylate groups in the OPN-mediated modulation of calcium oxalate (CaOx), the principal mineral phase found in kidney stones. To this end, crystallization was induced by addition of CaOx solution to ultrafiltered human urine containing either human kidney OPN (kOPN; 7 consecutive carboxylates, 8 phosphates) or synthesized peptides corresponding to residues 65-80 (pSHDHMDDDDDDDDDGD; pOPAR) or 220-235 (pSHEpSTEQSDAIDpSAEK; P3) of rat bone OPN. Sequence 65-80 was also synthesized without the phosphate group (OPAR). Effects on calcium oxalate monohydrate (COM) and dihydrate (COD) formation were studied by scanning electron microscopy. We found that controls form large, partly intergrown COM platelets; COD was never observed. Adding any of the polyelectrolytes was sufficient to prevent intergrowth of COM platelets entirely, inhibiting formation of these platelets strongly, and inducing formation of the COD phase. Strongest effects on COM formation were found for pOPAR and OPAR followed by kOPN and then P3, showing that acidity and hydrophilicity are crucial in polyelectrolyte-affected COM crystallization. At higher concentrations, OPAR also inhibited COD formation, while P3, kOPN and, in particular, pOPAR promoted COD, a difference explainable by the variations of carboxylate and phosphate groups present in the molecules. Thus, we conclude that carboxylate groups play a primary role in inhibiting COM formation, but phosphate and carboxylate groups are both important in initiating and promoting COD formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21234554     DOI: 10.1007/s00240-010-0360-8

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  39 in total

Review 1.  Renal cell-urinary crystal interactions.

Authors:  J C Lieske; F G Toback
Journal:  Curr Opin Nephrol Hypertens       Date:  2000-07       Impact factor: 2.894

Review 2.  Macromolecules and urolithiasis: parallels and paradoxes.

Authors:  Rosemary Lyons Ryall
Journal:  Nephron Physiol       Date:  2004

3.  Crystallization of calcium oxalates is controlled by molecular hydrophilicity and specific polyanion-crystal interactions.

Authors:  Bernd Grohe; Adam Taller; Peter L Vincent; Long D Tieu; Kem A Rogers; Alexander Heiss; Esben S Sørensen; Silvia Mittler; Harvey A Goldberg; Graeme K Hunter
Journal:  Langmuir       Date:  2009-10-06       Impact factor: 3.882

4.  Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily.

Authors:  H Shiraga; W Min; W J VanDusen; M D Clayman; D Miner; C H Terrell; J R Sherbotie; J W Foreman; C Przysiecki; E G Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-01       Impact factor: 11.205

5.  Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

Authors:  A Oldberg; A Franzén; D Heinegård
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

6.  Contribution of human uropontin to inhibition of calcium oxalate crystallization.

Authors:  J R Asplin; D Arsenault; J H Parks; F L Coe; J R Hoyer
Journal:  Kidney Int       Date:  1998-01       Impact factor: 10.612

7.  Phosphorylated osteopontin peptides suppress crystallization by inhibiting the growth of calcium oxalate crystals.

Authors:  J R Hoyer; J R Asplin; L Otvos
Journal:  Kidney Int       Date:  2001-07       Impact factor: 10.612

8.  A chemical model for the cooperation of sulfates and carboxylates in calcite crystal nucleation: Relevance to biomineralization.

Authors:  L Addadi; J Moradian; E Shay; N G Maroudas; S Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

Review 9.  Osteopontin and calcium stone formation.

Authors:  Jack G Kleinman; Jeffrey A Wesson; Jeremy Hughes
Journal:  Nephron Physiol       Date:  2004

10.  Scanning electron microscopic study of the effect of citrate and pyrophosphate on calcium oxalate crystal morphology.

Authors:  Y Shirane; S Kagawa
Journal:  J Urol       Date:  1993-12       Impact factor: 7.450

View more
  6 in total

1.  Incorporation of osteopontin peptide into kidney stone-related calcium oxalate monohydrate crystals: a quantitative study.

Authors:  Jared S Gleberzon; Yinyin Liao; Silvia Mittler; Harvey A Goldberg; Bernd Grohe
Journal:  Urolithiasis       Date:  2018-12-19       Impact factor: 3.436

2.  Alteration of urinary macromolecules by adsorption on surfaces, probably an important factor in urolithiasis.

Authors:  J M Baumann; B Affolter; U von Arx; M Noël
Journal:  Urolithiasis       Date:  2013-09-14       Impact factor: 3.436

3.  The paradoxical role of urinary macromolecules in the aggregation of calcium oxalate: a further plea to increase diuresis in stone metaphylaxis.

Authors:  J M Baumann; B Affolter
Journal:  Urolithiasis       Date:  2016-02-26       Impact factor: 3.436

4.  Kidney stones in primary hyperoxaluria: new lessons learnt.

Authors:  Dorrit E Jacob; Bernd Grohe; Michaela Geßner; Bodo B Beck; Bernd Hoppe
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

5.  Immunohistochemical localization and mRNA quantification of osteopontin and Tamm-Horsfall protein in canine renal tissue after potassium oxalate injection.

Authors:  Walaa Mohamaden; Heng Wang; Huawei Guan; Xia Meng; Jianji Li
Journal:  BMC Vet Res       Date:  2014-03-17       Impact factor: 2.741

6.  Peptides of Matrix Gla protein inhibit nucleation and growth of hydroxyapatite and calcium oxalate monohydrate crystals.

Authors:  Maria Goiko; Joshua Dierolf; Jared S Gleberzon; Yinyin Liao; Bernd Grohe; Harvey A Goldberg; John R de Bruyn; Graeme K Hunter
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.